1. Introduction
Primary eosinophilic gastrointestinal disorders (EGIDs) are emerging chronic/remittent inflammatory diseases of unknown etiology, which may involve any part of the gastrointestinal (GI) tract, leading to eosinophilic mucosal infiltration in the absence of secondary causes of intestinal eosinophilia [
1,
2,
3]. While eosinophilic esophagitis (EoE) is a well-characterized disease with established guidelines [
4,
5], nonesophageal EGIDs, including eosinophilic gastritis, gastroenteritis, and colitis, remain a clinical enigma [
1]. Although their pathogenic mechanisms are still unknown, EGIDs seems to be commonly associated with atopy and, to a lesser extent, autoimmunity [
1,
2]. EoE pathogenesis has been more extensively studied, and advances concerning the genetic and environmental contributors and cellular and molecular etiology have been achieved [
6]. EGIDs seem to be multifactorial diseases resulting from genetic predisposition, environmental risk factors, and intestinal dysbiosis, leading to the activation of T-helper type 2 (Th2) inflammation and impaired epithelial barrier [
1,
7]. To date, no studies have extensively assessed malnutrition in patients with EGIDs.
In all its forms, malnutrition includes undernutrition, inadequate intake of vitamins and/or minerals, overweight, and obesity [
8]. Undernutrition is a common complication of several chronic inflammatory GI diseases, mainly coeliac disease (CD) and Crohn’s disease, often associated with weight loss, failure to thrive, malabsorption, and vitamin deficiency. However, obesity and overweight are the main comorbidities of gastroesophageal reflux disease (GERD) and functional GI disorders, and are well-known risk factors of hepatic steatosis [
9,
10].
This review aims to summarize the current evidence on the nutritional status and malnutrition in patients with EGIDs, mainly focusing on the pediatric patients’ population and highlining the lack of nutritional management algorithms.
A review of articles was performed via the online database PubMed (
Table 1), following PRISMA guidelines [
11]. The literature review was performed in December 2020, including all publication years. All studies that met the following criteria were included: (1) case reports, case series, and cross-sectional and cohort studies published in English in peer-reviewed journals; (2) participants were children and adult patients diagnosed with EGIDs. Potentially eligible publications were manually screened and reviewed, and nonrelevant publications were excluded (
Figure 1).
2. Obese and Overweight EGID Patients
Obesity is a global public health problem associated with many chronic diseases, including type 2 diabetes, arterial hypertension, cardiovascular diseases, and asthma [
12]. Growing evidence supports the association between obesity and immune disorders, such as cancer, autoimmunity, and atopy [
13]. Some studies have suggested that pediatric obesity epidemy and obesity-related inflammation might at least in part be responsible for the significantly raised prevalence of allergic diseases [
13]. The relationship between asthma and obesity in children is widely demonstrated, and several observational studies have reported that obese children are more frequently affected by a severe phenotype of asthma, refractory to conventional therapies [
14,
15,
16,
17]. Additionally, data from the National Health and Nutrition Examination Study III (NHANES III) have described a positive association between body mass index (BMI) and atopy rates [
17]. However, a real link between obesity and other allergic disorders, such as allergic rhinitis, atopic dermatitis, as well as EGIDs, has not yet been extensively established [
18]. A few studies have assessed the role of body weight and BMI in children and adolescents with EoE, and no articles were published on EGIDs distal to the esophagus (
Table 2). There is evidence that most adults with EoE mainly have a good nutritional status and expected BMI values [
19,
20,
21,
22,
23,
24,
25,
26,
27]. Despite feeding or swallowing issues, EoE children did not generally report nutritional deficiency or impaired growth [
23]. Rezende et al. found that 82.8% of the enrolled EoE children had a good nutritional state, 11.4% were overweight, whereas 5.7% were underweight [
27]. Moreover, Jensen et al., 2019 reported that EoE children might present a slight impairment of height at diagnosis and achieve their expected growth, regardless of treatment modality [
21]. Finally, children with GERD and EoE had a weight-for-length (WFL) Z score at the 18th–13th percentiles; thus, they did not meet the criteria for failure to thrive (FTT) [
24].
To date, no research has investigated the possible pathogenetic role of obesity in EGID development. Putative explanations could probably be found in environmental and genetic risk factors and EGID-related comorbidities. The overall prevalence of EGIDs seems to higher in developed Western countries, where childhood obesity and atopic diseases were significantly increased through time [
7,
28]. Indeed, obesity and the Western lifestyle, mainly characterized by high calorie/fat consumption and reduced physical activity, might be directly related to the increased risk of developing allergic diseases, such as EGIDs [
13]. In a study in mice, Silva et al. demonstrated that obesity aggravated the immune histopathological characteristics of the EoE experimental model, reducing the regulatory cytokines profile (low expression of forkhead box P3, FOXP3, and interleukin 10, IL-10), increasing the inflammatory mediators (IL-5 and thymic stromal lymphopoietin, TSLP), and promoting tissue remodeling [
29]. These fascinating data might provide new insights about obesity as a possible EoE risk factor that might impair esophageal inflammation and symptoms.
Another possible pathogenetic mechanism might be the relationship between EoE and GERD. Diagnosis of GERD has also increased, especially in developed countries [
7]. In half of the infants with refractory vomiting and regurgitation, GERD was also expressed in the underlying cow’s milk allergy, and improved with a hydrolyzed formula [
30]. Several studies reported that GERD might play a possible pathogenetic role in esophageal eosinophilia, more relevant in PPI-responsive patients [
31]. Indeed, EoE and GERD are not mutually exclusive and might coexist [
4]. Although there are no exact data, four mechanisms have been proposed to explain this association: (1) GERD only causes esophageal eosinophilia; (2) GERD and EoE coexist but are independent phenomena; (3) EoE induces GERD; (4) GERD contributes to or induces EoE [
7,
31]. Acid reflux alters the esophageal epithelial barrier, leading to high intestinal permeability, with a subsequent passage of food allergens and release of inflammatory and eosinophil chemoattractant molecules might trigger EoE in susceptible subjects [
32].
On the other hand, the esophageal eosinophilic inflammation is also associated with the production of different proinflammatory cytokines that might impair peristalsis and the esophageal acid clearance [
7,
33]. The subepithelial fibrosis, a delayed complication of EoE, might also promote esophageal dysmotility and GERD-related symptoms [
31]. It is well described that being overweight and obese contribute to the development and worsening of GERD frequency and symptoms [
34,
35]. Obesity is notoriously involved in the pathogenesis of GERD [
23]. Visceral fat might mechanically induce reflux events, increasing the intra-abdominal pressure [
36]. Additionally, abdominal fat is metabolically active, activating macrophages, increasing and releasing proinflammatory cytokines and adipokines such as leptin [
23,
36].
Genes, obesity, and atopic diseases are linked. This association is well described in asthma patients, whereas no studies have been reported on EGID subjects. The β2-adrenergic (ADRB2) and glucocorticoid (NR3C1) receptor genes have been involved in the development of asthma and obesity [
13]. Similarly, polymorphisms of the fractalkine receptor gene (CX3CR1) have been associated with asthma, atopy, and obesity [
16]. However, no studies have described a genetic correlation between obesity/overweight and EGIDs.
Finally, EoE is characterized by chronic inflammation, specifically affecting the esophagus and generally sparing other GI tracts. This feature could clarify why EoE is not related to intestinal malabsorption and does not affect the bodyweight of adult patients.
The relationship between EGIDs, overweight, and obesity is still speculative, and further studies are required to confirm these clinical findings.
3. Undernutrition and Failure to Thrive in EGIDs Patients
Although poorly investigated, EGIDs may also be complicated by undernutrition and FTT for pathogenetic mechanisms similar to those reported in inflammatory bowel disease (IBD) patients [
37]. FTT is one of the most commonly described clinical complications in children with EoE [
3,
38], although the exact prevalence has never been documented. Retrospective studies have reported that the prevalence of FTT ranges from 10.5% to 24% of EoE patients with different age-related rates (
Table 3) [
39,
40,
41,
42,
43,
44]. In a large retrospective study, Spergel et al. demonstrated that FTT mainly characterized young children (2.8 ± 3.2 years) [
44]. Moreover, Alhmoud et al. reported FTT and weight loss only in children with EoGE, and 15% of these had severe mucosal involvement leading to malabsorption [
41].
Several factors may negatively impact the nutritional status of EGIDs patients (
Table 4), mostly children. Firstly, children with EoE more likely present feeding disorders, recurrent vomiting, or regurgitation due to the esophageal inflammation and dysfunction, which can severely impair the adequate intake of foods and nutrients [
2,
3]. EGIDs are emerging GI disorders, therefore the diagnostic delay was often reported in adolescents and adults, who can consequently develop esophageal strictures due to the chronic inflammation and fibrous tissue deposition, prolonging clinical symptoms and patient feeding discomfort [
45].
Secondly, low compliance to treatment is one of the main reasons for therapeutic failure and persistent active EoE, especially in adolescents and adults [
46]. Chronic GI symptoms and impaired oral food intake, due to the sustained esophageal inflammation and continued low-grade antigen exposure, through limited dietary compliance are other possible explanations for undernutrition.
Thirdly, children, adolescents, and adults with previous food impaction episodes may have a high risk of developing anxiety and eating disorders, such as nervous anorexia and food avoidance, leading to an inadequate nutrient intake [
46,
47]. In a case-control study, Wu et al. found that most children with EGIDs had feeding behavioral problems compared to healthy controls [
48]. Another study showed that 16.5% of EGID children had feeding issues, such as food refusal, low volume, and variety of intake, grazing, and spitting food out [
49]. Moreover, 21% of these children were also complicated by FTT, suggesting that feeding issues may impair the regular childhood oral intake contributing to undernutrition and growth failure [
49].
Additionally, a retrospective multicentric U.S. study of Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) reported that 41% of children and adolescents with nonesophageal EGIDs might have a multisite GI inflammation [
50]. This finding suggests that the persistent GI inflammation and subsequent abnormal intestinal permeability may be possible reasons for nutrients loss and higher caloric and protein requirements in patients with EGIDs distal to the esophagus [
24].
Moreover, the association between EoE and other allergic conditions is well established and might be a potential further reason for FTT and undernutrition in EGIDs children. Children with EGIDs have an excessive prevalence of atopic dermatitis, IgE-mediated food allergy, asthma, and allergic rhinitis, potentially affecting the expected growth [
51]. Moreover, several reports have suggested that EGIDs may also be frequently associated with chronic non-allergic comorbidities that might compromise adequate child growth, feeding behavior, and quality of life [
46]. In a cross-sectional study, Capuccilli et al. demonstrated that children with EoE also had higher rates of coexisting non-atopic diseases, including IBD (0.7%) and CD (5.6%), as well as a higher prevalence of autism spectrum disorders (ASDs) (7.5%), type 1 diabetes mellitus (1.2%) and cystic fibrosis (0.9%) [
52].
Finally, an important unanswered question is whether therapies can influence FTT. Paquet et al. have reported that EoE-related FTT resolved in 62% of affected children, suggesting that medical interventions might be helpful not only for disease-remission but also for clinical complications [
42]. However, these results cannot be generalized because this study was retrospective and based on a small number of patients (15 patients with EoE + FTT). On the other hand, it was widely described that impaired growth and inadequate intake of macro- and micronutrients are possible complications of restrictive food elimination diets, which are pivotal therapeutical approaches of several pediatric illnesses, including EGIDs [
1]. Several clinical factors might induce protein–calorie malnutrition and impaired food intake with weight loss, FTT, and delayed puberty. These findings underly the importance of assessing potential risk factors that may bring dietary limitations and normal growth of children with EGIDs.
4. Vitamin D Deficiency in EGIDs
Low serum vitamin D levels have been proposed to explain the increased prevalence of atopic and autoimmune diseases in Western countries [
53]. Several efforts have focused on the role of vitamin D in the contribution of chronic dysregulated inflammation and its modulation [
53]. Prevalence of EoE is higher in Western countries and cold climate zones, suggesting a possible association with low serum vitamin D levels [
7]. Increasingly, significant evidence has shown a consistent link between vitamin D deficiency—due to the quality of diet, lack of exposure to sunlight—and the risk of atopy, as already described for asthma, allergic rhinitis, food allergy, and atopic dermatitis [
7].
A systematic review has reported that low vitamin D prevalence varied widely in enrolled studies (0–52%) and did not improve with therapy [
24,
54] (
Table 5). Low levels of vitamin D were described in 42% of adults and 50% of children with EoE, prevailing in patients with symptoms of food impaction [
54,
55]. In a case-control study of 69 children, Waterhouse et al. reported that patients with EoE and GERD had low vitamin D levels compared to normal controls, but without a significant difference [
56]. To date, no study assessed other vitamins in EGIDs and serum vitamin D in patients with EGIDs beyond the esophagus.
Although there is emerging evidence of vitamin D in the development of the immune system and pathogenesis of allergic diseases, such as asthma, atopic dermatitis, and food allergy, no studies have evaluated its possible role in EGIDs development and remission [
53]. Furthermore, based on the design of available studies (cross-sectional data analysis) no cause–effect relationship can be inferred. It is reasonable to argue that toddlers and young children with EoE could present with feeding difficulty and refusal, with subsequent nutrient deficiencies, thus malnutrition. Besides, food elimination diets, mostly milk-free diets, could increase the risk of vitamin D deficiency in EoE patients, as reported in children with cow’s milk allergy [
57,
58].
5. Management of EGIDs Patients: From Traditional Tools and Treatments to Future Insights
Diagnoses of EGIDs are not always straightforward and require chronic GI symptoms, coupled with suggestive endoscopic findings, prevalent eosinophilic inflammation (
15 eosinophils/high-power field (HPF) for EoE) in biopsy specimens, and the exclusion of other causes of GI eosinophilia [
1,
4,
5]. Symptoms of EGID are generally heterogeneous and often overlap with other conditions and may occur concomitantly. In EoE, the eosinophilic inflammation leads to progressive esophageal dysfunction, mainly characterized by feeding refusal and vomiting in children, and dysphagia, heartburn, and food bolus impaction in adolescents and adult patients [
3]. Patients do not always appear to have feeding or eating disorders; only 24% of younger patients showed a failure to thrive. As reported in this review, most patients were normal weight or even obese. A meticulous evaluation of the patient’s symptoms should be recommended, and the clinician should ask the right questions to detect suspicious eating habits (
Table 6) [
59].
Although several research efforts have produced fascinating progress in the diagnosis and management of EGIDs, especially EoE, the only currently available tool to confirm the clinical suspicion is GI endoscopy with a biopsy [
4,
5]. Nevertheless, surrogate measures for EoE activity and response to therapy, such as the esophageal String test, transnasal esophagoscopy, and Cytosponge, have emerged as effective, less invasive tools for obtaining esophageal tissue samples [
60,
61].
Since EoE was initially identified in the mid-1990s, multiple EoE treatment strategies have been developed. Dietary treatment represented the first-line therapeutical approach for EGIDs [
1,
4,
5]. Elemental (exclusive amino acid-based formulas) and six-food (milk, wheat, egg, soy, fish and shellfish, nuts) elimination diet (SFED) are the two main nutritional methods for EGID management with high rates of remission [
1,
4,
5]. Trials have reported that a significant proportion of EoE patients achieved histologic remission on less restrictive (two/four food elimination) diets. Thus, personalized dietary strategies might offer the greatest success, improving the nutritional status and quality of life of affected subjects [
60]. Successful targeted removal of specific foods based on allergy tests have been reported as case reports. However, targeted food removal might not be effective and is not recommended, because response to therapy did not seem to correspond to food allergies identified by skin prick testing or measuring serum food-specific IgE concentrations [
62].
Swallowed steroids are alternative EGID treatments to diet-based interventions. The two most common approaches include swallowed fluticasone and viscous budesonide [
4,
5]. Comparisons between elimination diets and swallowed steroids are difficult, due to the heterogeneity of available studies. Meta-regression analyses showed that both therapeutical approaches are generally equivalent at inducing histologic remission in EGIDs patients [
63].
Unfortunately, a significant population of patients with EGIDs has persistent active disease. Therefore, several ongoing efforts identify promising biological therapies beyond diet or steroid strategies [
60,
64]. Future efforts should be targeted to particular EGID endotypes using traditional and biologic therapies to achieve a new and high disease control degree.
How to Manage Malnutrition in Children with EGIDs?
This study suggests that a multidisciplinary approach (allergist, gastroenterologist, nutritionist, psychologist) is a key winner of EGIDs management (
Figure 2), especially in children with allergic and non-allergic phenotypes. Moreover, the nutritional status assessment may help recognize patients with an inadequate nutrient intake, especially if they require restrictive food elimination diets (
Figure 3).
This review summarized evidence on pediatric EGIDs malnutrition and underly conflicting findings. While some studies have reported normal or high BMI, especially in adults with coexisting GERD, FTT might mostly afflict young children. As reported for allergic diseases, EGIDs may also show vitamin D deficiency. However, no study has assessed how intestinal inflammation or EGIDs therapies may impact serum vitamin D and bone metabolism. Despite an inadequate investigation, EGID malnutrition is a relevant clinical field that requires further efforts to strengthen the efficacy of therapies and improve the patients’ quality of life.